Michael Tomsicek
Director/Board Member bij MILESTONE PHARMACEUTICALS INC.
Vermogen: 82 835 $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Peter Blume-Jensen | M | 62 | 6 jaar | |
Thomas DesRosier | M | 69 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 11 jaar |
Kristina Masson | M | 44 | 6 jaar | |
Joseph Oliveto | M | 56 | 7 jaar | |
Robert Wills | M | 70 | 4 jaar | |
Meredith Schaum | F | - |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 11 jaar |
John Greene | M | 58 | 5 jaar | |
Derek DiRocco | M | 43 | 3 jaar | |
Katherine High | M | 72 | 5 jaar | |
Lukas Jeker | M | - |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | - |
Lisa Giles | F | 65 | 4 jaar | |
Harold Edward Fleming | M | 61 | 3 jaar | |
Richard Pasternak | M | 75 | 5 jaar | |
Howard J. Dreskin | M | - |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 17 jaar |
Pamela S. Sears | M | - |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 22 jaar |
Erick Gamelin | M | 67 | 3 jaar | |
Sharon Shacham | M | 53 | 4 jaar | |
Debra Liebert | F | 67 | 9 jaar | |
Doug Treco Treco | M | 66 | 4 jaar | |
Adam Levy | M | - | 1 jaar | |
David Bharucha | M | 62 | 2 jaar | |
Anita Holz | F | - | 2 jaar | |
Thomas Fuchs | M | - |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | - |
Debbie K. Everidge | F | - | 3 jaar | |
Kimberly Sheehan | F | - | 2 jaar | |
Jeffrey Blizard | M | 54 | 7 jaar | |
Karen Mahoney | F | 80 | 7 jaar | |
Roshan Girglani | M | - | 2 jaar | |
Karl Hsu | M | - | - | |
Robert Perez | M | 59 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 11 jaar |
Amit Hasija | M | 51 | 5 jaar | |
Mary Miller | F | 50 | - | |
Jeff Nelson | M | 42 | 4 jaar | |
Rasmus Holm-Jorgensen | M | 53 | 2 jaar | |
Alexander Mayweg | M | 49 |
Cimeio Therapeutics AG
Cimeio Therapeutics AG Packaged SoftwareTechnology Services Cimeio Therapeutics AG is an applied gene editing and immunotherapy company based in Basel, Switzerland. Cimeio is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip) that have the potential to transform hematopoietic stem cell transplant. The Swiss company's technology platform is based on the design and expression of modified variants of naturally occurring cell surface proteins in hscs. These novel variants maintain their function but are resistant to depletion when targeted by a paired immunotherapy which has high affinity for the wild-type version of these proteins. Cimeio is the leader of the field of epitope editing and is developing a portfolio of shielded-cell & immunotherapy pairs™ (scip), novel immunotherapies which have the potential to transform treatment of hematologic diseases. The company develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in hscs. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. The company was founded by Lukas Jeker and the CEO is Thomas Fuchs. | - |
Jean-Marie Cuillerot | M | - | - | |
Ivana Magovcevic-Liebisch | M | 55 | - | |
Charles Baum | M | 65 | 1 jaar | |
Thomas Reps | M | - |
University of Wisconsin
| 39 jaar |
Stephen Kennedy | M | 67 | 5 jaar | |
Lorenz Muller | M | 60 | 7 jaar | |
Guy Rousseau | M | - | 8 jaar | |
Sherwood L. Gorbach | M | 89 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 19 jaar |
Seth Fischer | M | 68 | 1 jaar | |
Rajshree Kandadai | F | - | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Michael Chang | M | 73 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 15 jaar |
Henry McKinnell | M | 81 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 2 jaar |
Paul Truex | M | 55 | 10 jaar | |
Maya K. Bittar | F | - |
University of Wisconsin
| 9 jaar |
David McGirr | M | 69 | 12 jaar | |
Donald A. Johnson | M | - |
University of Wisconsin
| 11 jaar |
Azita Saleki-Gerhardt | M | 60 |
University of Wisconsin
| 8 jaar |
Louis E. Lataif | M | 84 | 10 jaar | |
Jeff A. Simmons | M | - |
University of Wisconsin
| 9 jaar |
Christopher D. van Gorder | M | 71 | 6 jaar | |
Scott Ray Powell | M | - |
University of Wisconsin
| 7 jaar |
Paul A. Stone | M | 60 |
University of Wisconsin
| 7 jaar |
Tim L. Voigtman | M | - |
University of Wisconsin
| 8 jaar |
Yu Neng Lim | M | 61 |
University of Wisconsin
| 5 jaar |
Jun Ni | M | 61 |
University of Wisconsin
| 4 jaar |
Laura Agran | F | - |
University of Wisconsin
| 5 jaar |
Chantell Johnson | F | - |
University of Wisconsin
| 6 jaar |
Bart F. Reuter | M | - |
University of Wisconsin
| 8 jaar |
Chris Nisbet | M | - |
University of Wisconsin
| 9 jaar |
Tamara Joseph | F | 61 | 4 jaar | |
Timothy L. Maness | M | 63 | 1 jaar | |
Mohammad Khalid Osama Asfour | M | 59 |
University of Wisconsin
| 6 jaar |
Thomas Honggo Setjokusumo | M | 60 |
University of Wisconsin
| 3 jaar |
Armand Ardika | M | 46 |
University of Wisconsin
| 6 jaar |
Dan Nickow | M | - |
University of Wisconsin
| 5 jaar |
Nilesh Kumar | M | 47 | 2 jaar | |
Jonathan F. McAnulty | M | - |
University of Wisconsin
| 5 jaar |
Kala Subramanian | M | 57 | - | |
Marco Boorsma | M | 49 | 2 jaar | |
Greg J. Schroeder | M | - |
University of Wisconsin
| 8 jaar |
Nancy Hutson | M | 74 | 7 jaar | |
Paul Leff | M | - |
University of Wisconsin
| 5 jaar |
Pablo Cagnoni | M | 60 | 4 jaar | |
Joseph Y. Chang | M | 71 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 15 jaar |
Timothy Mattke | M | 48 |
University of Wisconsin
| 5 jaar |
Jeannine M. Rivet | F | 76 | 6 jaar | |
Henri A. Termeer | M | 78 | 30 jaar | |
Lonnie Moulder | M | 66 | 5 jaar | |
Jay Robert Sekelsky | M | 65 |
University of Wisconsin
| 6 jaar |
Robert Zerbe | M | 73 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 4 jaar |
Mike Reckmeyer | M | - |
University of Wisconsin
| 7 jaar |
Jim Stephenson | M | - |
University of Wisconsin
| 6 jaar |
Thomas Woiwode | M | 52 | 5 jaar | |
Kurt von Emster | M | 56 | 4 jaar | |
Tom Cole | M | - |
University of Wisconsin
| - |
Vince Russo | M | - |
University of Wisconsin
| 6 jaar |
Reik Watson Read | M | - |
University of Wisconsin
| 6 jaar |
N. Coles | M | 63 | 2 jaar | |
Jill Marie Grueninger | F | - |
University of Wisconsin
| 6 jaar |
Anthony Altig | M | 68 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 6 jaar |
Peter E. Grebow | M | 77 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 4 jaar |
James Thalacker | M | - |
University of Wisconsin
| 8 jaar |
Mark Auerbach | M | 85 |
Optimer Pharmaceuticals LLC
Optimer Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Optimer Pharmaceuticals LLC operates as a biopharmaceutical company. It is focused on discovering, developing, and commercializing innovative hospital specialty products. Optimer Pharmaceuticals primarily concentrates on developing DIFICID and other fidaxomicin products. The company was founded by Michael N. Chang in 1998 and is headquartered in Jersey City, NJ. | 8 jaar |
Tirtha Chakraborty | M | 51 | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 66 | 66.67% |
Canada | 19 | 19.19% |
Zwitserland | 14 | 14.14% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Michael Tomsicek
- Persoonlijk netwerk